"the vepoloxamer+HU patients’ mean duration was 26 hours shorter (p=0.02) than the eight hour reduction in the overall group. If all other design elements remained the same as the first Phase 3, the 10% absolute increase in HU usage should in our estimation push the mean duration up two hours to ten. We believe this metric alone would be enough by itself to push the p-value <0.05 in that 255 patient study. "
News 
Market Data 
Discover 
